Yousif Capital Management LLC Sells 572 Shares of Haemonetics Corporation (NYSE:HAE)

Yousif Capital Management LLC decreased its stake in shares of Haemonetics Corporation (NYSE:HAE) by 3.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 17,702 shares of the medical instruments supplier’s stock after selling 572 shares during the quarter. Yousif Capital Management LLC’s holdings in Haemonetics were worth $1,125,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. TD Waterhouse Canada Inc. bought a new stake in Haemonetics in the fourth quarter valued at about $25,000. Covestor Ltd increased its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 439 shares during the period. Whittier Trust Co. bought a new stake in Haemonetics in the fourth quarter valued at about $62,000. Parkside Financial Bank & Trust increased its stake in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after acquiring an additional 240 shares during the period. Finally, AlphaQuest LLC increased its stake in Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after acquiring an additional 1,826 shares during the period. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HAE shares. Needham & Company LLC lowered their target price on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Raymond James Financial reissued a “strong-buy” rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Wall Street Zen cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $100.00 target price on shares of Haemonetics in a research note on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.89.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $69.99 on Thursday. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of 21.15, a P/E/G ratio of 1.12 and a beta of 0.36. Haemonetics Corporation has a 1-year low of $55.30 and a 1-year high of $94.99. The firm’s 50-day moving average price is $65.79 and its two-hundred day moving average price is $68.80.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period in the prior year, the business earned $0.90 earnings per share. Haemonetics’s quarterly revenue was down 3.5% on a year-over-year basis. On average, equities analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.